Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-069192
Filing Date
2023-12-11
Accepted
2023-12-11 07:02:02
Documents
69
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lxeo-20230930.htm   iXBRL 10-Q 2457461
2 EX-31.1 lxeo-ex31_1.htm EX-31.1 11607
3 EX-32.1 lxeo-ex32_1.htm EX-32.1 6549
  Complete submission text file 0000950170-23-069192.txt   8940942

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lxeo-20230930_lab.xml EX-101.LAB 469591
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lxeo-20230930_cal.xml EX-101.CAL 50278
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lxeo-20230930_pre.xml EX-101.PRE 403819
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lxeo-20230930_def.xml EX-101.DEF 267075
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lxeo-20230930.xsd EX-101.SCH 60015
63 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20230930_htm.xml XML 1393781
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41855 | Film No.: 231476897
SIC: 2836 Biological Products, (No Diagnostic Substances)